# Xellar Biosystems

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/xellar-biosystems

- Industry: Biotechnology
- Headquarters: Boston, US
- Website: www.xellarbio.com
- Total disclosed funding: $72M
- Latest round: Series A (Jun 29, 2026)
- Investors on record: 13

## About

Established in 2021 and based in Boston, US, Beijing Xellar Biosystems Co. Ltd., doing business as Xellar Biosystems, operates a drug discovery platform that integrates organ chip technology and artificial intelligence. The company established a research and development laboratory in Boston. The co-founder and chief executive officer, Xin Xie, completed post-doctoral research in organ chip and engineered life systems at Harvard University and later worked at TransMedics. In June 2026, the firm raised approximately CNY 200 million in series A+ funding.

The company works with pharmaceutical and biotechnology customers to provide drug discovery services based on organ chip technology and three dimensional cellular models. Its platform integrates microfluidic organ models, high content cell imaging, computer vision, and artificial intelligence to support drug safety assessment, efficacy analysis, and treatment response simulation. The company’s core product is the EPIC technology platform.

The company generates revenue from providing artificial intelligence enabled drug discovery services and licensing its proprietary technology platform to pharmaceutical and biotechnology companies.

The company plans to use the series A+ fundingto construct its 3D Bio Intelligence platform, deploy automated experimental systems, and develop Virtual Cells and Biological World Models to establish a humanized data infrastructure for drug discovery.

## Funding rounds

- Series A, Jun 29, 2026, $29M — Oriental Fortune Capital, GF Xinde Investment, Tsing Song Capital, Shanghai Growth Investment, Cedarlake Capital, Yael Capital
- Series A, Apr 2, 2026, $29M — Legend Capital, XtalPi Inc., China Life Capital, Yael Capital
- Angel, Jul 16, 2024, $14M — Legend Capital, Tiantu Capital, Zhengxuan Capital, Yael Capital, TriApex Laboratories Co., Ltd.
- Angel, Aug 30, 2022 — Legend Capital, ZhenFund, Yael Capital

## Investors

- Legend Capital — Angel, Series A
- ZhenFund (https://capitalatlas.ai/funds/zhenfund) — Angel
- Yael Capital (https://capitalatlas.ai/funds/yael-capital) — Angel, Series A
- Tiantu Capital (https://capitalatlas.ai/funds/tiantu-capital) — Angel
- Zhengxuan Capital (https://capitalatlas.ai/funds/zhengxuan-capital) — Angel
- TriApex Laboratories Co., Ltd. — Angel
- XtalPi Inc. — Series A
- China Life Capital — Series A
- Oriental Fortune Capital (https://capitalatlas.ai/funds/oriental-fortune-capital) — Series A
- GF Xinde Investment (https://capitalatlas.ai/funds/gf-xinde-investment) — Series A
- Tsing Song Capital (https://capitalatlas.ai/funds/tsing-song-capital) — Series A
- Shanghai Growth Investment (https://capitalatlas.ai/funds/shanghai-growth-investment) — Series A
- Cedarlake Capital (https://capitalatlas.ai/funds/cedarlake-capital) — Series A